Amicus Therapeutics Valuation
| FOLD Stock | USD 5.96 0.33 5.25% |
At this time, the firm appears to be undervalued. Amicus Therapeutics shows a prevailing Real Value of $8.16 per share. The current price of the firm is $5.96. Our model approximates the value of Amicus Therapeutics from analyzing the firm fundamentals such as Current Valuation of 2.03 B, profit margin of (0.05) %, and Return On Equity of -0.18 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Amicus Therapeutics' valuation include:
Undervalued
Today
Please note that Amicus Therapeutics' price fluctuation is somewhat reliable at this time. Calculation of the real value of Amicus Therapeutics is based on 3 months time horizon. Increasing Amicus Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Amicus stock is determined by what a typical buyer is willing to pay for full or partial control of Amicus Therapeutics. Since Amicus Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Amicus Stock. However, Amicus Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 5.96 | Real 8.16 | Target 15.82 | Hype 5.95 | Naive 6.13 |
The real value of Amicus Stock, also known as its intrinsic value, is the underlying worth of Amicus Therapeutics Company, which is reflected in its stock price. It is based on Amicus Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Amicus Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Amicus Therapeutics helps investors to forecast how Amicus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Amicus Therapeutics more accurately as focusing exclusively on Amicus Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Amicus Therapeutics' intrinsic value based on its ongoing forecasts of Amicus Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Amicus Therapeutics' closest peers. If more than one evaluation category is relevant for Amicus Therapeutics we suggest using both methods to arrive at a better estimate.
Amicus Therapeutics Cash |
|
Amicus Valuation Trend
Comparing Amicus Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Amicus Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Amicus Therapeutics Total Value Analysis
Amicus Therapeutics is currently expected to have valuation of 2.03 B with market capitalization of 1.84 B, debt of 443.64 M, and cash on hands of 386.84 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Amicus Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.03 B | 1.84 B | 443.64 M | 386.84 M |
Amicus Therapeutics Investor Information
About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 0.09. Amicus Therapeutics last dividend was issued on the 31st of August 2009. Based on the key indicators related to Amicus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Amicus Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.Amicus Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Amicus Therapeutics has an asset utilization ratio of 67.3 percent. This indicates that the Company is making $0.67 for each dollar of assets. An increasing asset utilization means that Amicus Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Amicus Therapeutics Ownership Allocation
The majority of Amicus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Amicus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Amicus Therapeutics. Please pay attention to any change in the institutional holdings of Amicus Therapeutics as this could imply that something significant has changed or is about to change at the company.Amicus Therapeutics Profitability Analysis
The company reported the previous year's revenue of 528.29 M. Net Loss for the year was (56.11 M) with profit before overhead, payroll, taxes, and interest of 492.07 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Amicus Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Amicus Therapeutics and how it compares across the competition.
About Amicus Therapeutics Valuation
The stock valuation mechanism determines Amicus Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Amicus Therapeutics. We calculate exposure to Amicus Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Amicus Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 475.4 M | 499.1 M | |
| Pretax Profit Margin | (0.05) | (0.06) | |
| Operating Profit Margin | 0.05 | 0.05 | |
| Net Loss | (0.11) | (0.11) | |
| Gross Profit Margin | 0.90 | 0.94 |
Amicus Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Amicus Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 304.4 M | |
| Forward Price Earnings | 49.0196 |
Amicus Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Amicus Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Amicus we look at many different elements of the entity such as Amicus's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Amicus Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Amicus Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Amicus Therapeutics' worth.Complementary Tools for Amicus Stock analysis
When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |